IBRN vs PSIL: Holdings Overlap & Returns

Over the year to Nov 13, 2026, IBRN returned +19.8% to PSIL's +18.6%; 11% of their weight is in the same names.

Return gap
+1.2 pts1 year to Nov 13, 2026: IBRN ahead, total return
Fee gap
0.53 ptsA year: IBRN 0.47%, PSIL 1.00%, per filings dated Nov 21, 2025 and Oct 28, 2026
Overlap
11%Share of the two books held in common, holdings dated Nov 12, 2026 and Jun 30, 2026
Net flow
–Needs daily flows for both funds
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
IBRN and PSIL · 1 year

Growth of 100

IBRN +19.8%PSIL +18.6%
Growth of 100 in IBRN and PSIL over 1 year, Nov 13, 2025 to Nov 13, 2026, with distributions reinvested. IBRN ends at 119.8 (+19.8%), PSIL at 118.6 (+18.6%).

IBRN +19.8%, PSIL +18.6%: IBRN +1.2 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.

Share

Use this comparison

Alert

IBRN and PSIL flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag the order size

Cost to trade

Hypothetical. A $10,000 order in IBRN costs about $16.00 one way and $32.00 in and out, at a median spread of 0.32%. The 0.32% spread is IBRN’s 30-day median, from iShares (fund page).

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in PSIL for 10 years at 1.00% a year costs about $1,620 in fees and lost growth; IBRN at 0.47% would cost $778. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

IBRN · 1 year to Nov 13, 202695% of its weight is outside the S&P 500
95% of its weight is outside the S&P 5005% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.5%95%inof its weight outside the S&P 500active share 100% · top ten 45% of the fund · 67 holdings as published by its issuer for Nov 12, 2026 · Nasdaq-100: 0% in95% of its weight is outside the S&P 5005% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.5%95%5% of its weight in S&P 500 companiesof its weight outside the S&P 500active share 100% · Nasdaq-100: 0% in

5% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.

PSIL · 1 year to Nov 13, 202692% of its weight is outside the S&P 500
92% of its weight is outside the S&P 5008% of PSIL's weight is in S&P 500 companies and 92% is outside the index. Holdings as of Jun 30, 2026.8%92%inof its weight outside the S&P 500active share 98% · top ten 69% of the fund · 27 holdings as filed for Jun 30, 2026 · Nasdaq-100: 0% in92% of its weight is outside the S&P 5008% of PSIL's weight is in S&P 500 companies and 92% is outside the index. Holdings as of Jun 30, 2026.8%92%8% of its weight in S&P 500 companiesof its weight outside the S&P 500active share 98% · Nasdaq-100: 0% in

8% of PSIL's weight is in S&P 500 companies and 92% is outside the index. Holdings as of Jun 30, 2026.

Key numbers

IBRN in the S&P 500
5.3%
PSIL in the S&P 500
7.8%
IBRN total return, 1 year
+19.8%
PSIL total return, 1 year
+18.6%

IBRN costs 0.53 points a year less; their one-year returns differ by 1.2 points; PSIL is 4.9 times larger.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year+19.8%+18.6%
Below its all-time high15.9%, high on Aug 19, 202678.3%, high on Sep 22, 2021
What it tracksTherapeutics and medical devicesTherapeutics and medical devices
Expense ratio0.47%1.00%
Net assets, as of Nov 12, 2026$8.6m$42m
Holdings in common11%

The numbers behind it

Net assets on Nov 12, 2026: $8.6m for iShares Neuroscience and Healthcare ETF and $42m for AdvisorShares Psychedelics ETF.

Holdings in common uses holdings dated Jun 30, 2026 and Nov 12, 2026.

What they share

By the books each fund has filed, IBRN and PSIL hold 11% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 12, 2026.

0half (50%)100%

half

11% in common

Held in common

Show all 5 holdings
NEUROCRINE BIOSCIENCES5.09%4.38%
Alkermes Public Limited Company4.75%4.30%
ALTO NEUROSCIENCE1.60%4.20%
BRIGHT MINDS BIOSCIENCES0.27%3.83%
SUPERNUS0.00%2.89%

Only in IBRN

Show all 8 holdings
BIOGEN5.33%
EDGEWISE THERAPEUTICS4.96%
ARGENX SE ADR4.43%
PRAXIS PRECISION MEDICINES4.30%
PTC THERAPEUTICS4.29%
AXOGEN4.28%
DIANTHUS THERAPEUTICS3.98%
SK BIOPHARMACEUTICALS LTD3.80%

Only in PSIL

Show all 8 holdings
DEFINIUM THERAPEUTICS INC12.85%
COMPASS PATHWAYS PLC11.45%
ATAIBECKLEY INC10.47%
RELMADA THERAPEUTICS INC6.84%
NRX PHARMACEUTICALS INC6.07%
CYBIN INC4.36%
GH RESEARCH PLC4.31%
ABBVIE INC4.14%

Side by side

Open the table
FundiShares Neuroscience and Healthcare ETF · Holds 67 stocks in therapeutics and medical devices, 5% of its weight in S&P 500 companiesAdvisorShares Psychedelics ETF · Holds 27 stocks in therapeutics and medical devices, 8% of its weight in S&P 500 companies
IssueriSharesAdvisorShares
ThemeTherapeutics and medical devicesTherapeutics and medical devices
In the S&P 5005.3%7.8%
Active share vs the S&P 500100.0%98.4%
In the Nasdaq-1000.0%0.0%
Holdings6727
Top ten, share of the fund45.2%69.2%
Expense ratio0.47%1.00%
Fee for the differing part0.47%1.02%
Total return, 1 year+19.8%+18.6%
vs its benchmarknot measurednot measured
Below its high−15.9%−78.3%
Net assets, as of Nov 12, 2026$8.6m$42m

As of Nov 13, 2026. Source: ETFIQ.

Window by window

Open the table
3 months−12.6%−23.9%
6 months−1.7%−3.7%
1 year+19.8%+18.6%
3 years+67.5%+62.8%
Since launch (Not the same days: IBRN Aug 2022 · PSIL Sep 2021)+41.2%−77.7%

About IBRN

By weight, 5% of IBRN's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 45% of the fund across 67 positions, as published by its issuer for Nov 12, 2026.

More

Over the year to Nov 13, 2026 the fund returned +19.8% with distributions reinvested. It sits 15.9% below its all-time high of Aug 19, 2026.

About PSIL

By weight, 8% of PSIL's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 69% of the fund across 27 positions, as filed for Jun 30, 2026.

More

Over the year to Nov 13, 2026 the fund returned +18.6% with distributions reinvested. It sits 78.3% below its all-time high of Sep 22, 2021.

11% of the two portfolios are the same securities at the same weight.

Questions people ask

Do IBRN and PSIL hold the same stocks?

By their latest filings, 11% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, IBRN or PSIL?

IBRN has 5% of its weight in S&P 500 names and PSIL has 8%, so IBRN differs more from the index.

Which is cheaper, IBRN or PSIL?

IBRN charges 0.47% a year and PSIL charges 1.00%, so IBRN is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, IBRN against PSIL, data as of Nov 13, 2026. https://etfiq.com/compare/themes/ibrn-vs-psil

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.